Use of an effective amount of entacapone ((2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2- enamide), or a pharmaceutically-acceptable salt thereof, particularly in conjunction with a second, different anti-weight gain medicament, whether copackaged or coformulated, for the manufacture of a medicament for the treatment of an obesity related disease or a symptom of an obesity related disease.